真菌性角膜炎治療の世界市場

真菌性角膜炎治療の世界市場は2030年までに14億米ドルに達する

2024年に9億6,520万米ドルと推定される真菌性角膜炎治療の世界市場は、分析期間2024-2030年にCAGR 6.1%で成長し、2030年には14億米ドルに達すると予測されます。本レポートで分析したセグメントの一つであるアゾール類は、CAGR5.8%を記録し、分析期間終了時には6億2,750万米ドルに達すると予想されます。エキノカンディン類セグメントの成長率は、分析期間中CAGR 7.0%と推定されます。

米国市場は2億6,300万米ドルと推定、中国はCAGR9.5%で成長すると予測

米国の真菌性角膜炎治療市場は、2024年に2億6,300万米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 9.5％を辿り、2030年までに2億7,910万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.0％と5.9％と予測されています。欧州では、ドイツがCAGR 4.0%で成長すると予測されています。

世界の真菌性角膜炎治療市場- 主要動向と促進要因のまとめ

なぜ効果的な真菌性角膜炎治療の需要が高まっているのか？

真菌性角膜炎は、フザリウム菌、アスペルギルス菌、カンジダ菌などの真菌病原体によって引き起こされる重篤な角膜感染症であり、特に熱帯・亜熱帯地域において、世界の健康問題として浮上しています。この疾患の罹患率の増加は、主に農業活動の増加、外傷関連感染、コンタクトレンズの誤用、免疫システムの低下と関連しています。診断の遅れや不十分な治療は、角膜の瘢痕化、視力障害、失明につながる可能性があり、より効果的な治療介入が必要です。ナタマイシン、アムホテリシンB、ボリコナゾールなどの従来の抗真菌治療が依然として標準的な選択肢であるが、薬剤耐性と限られたバイオアベイラビリティが依然として課題となっています。真菌性角膜炎の治療において、より高度で標的を絞った、侵襲性の低い治療法に対する需要が大幅に高まり、新規抗真菌剤、併用療法、革新的なドラッグデリバリー機構の研究が活発化しています。

製薬会社や研究機関は、角膜への浸透性を向上させ、耐性真菌に対する有効性を高めた次世代抗真菌薬の開発に積極的に取り組んでいます。ナノエマルジョンやリポソームキャリアなどのナノテクノロジーに基づく製剤は、薬剤の吸収を促進し、抗真菌剤の眼表面での滞留時間を延長するために研究されています。さらに、抗真菌ペプチドや免疫療法などの新しい治療法を研究する臨床試験が進行中であり、真菌性角膜炎治療における個別化医療へのシフトを示しています。真菌症に伴う罹患率の高さから、世界の保健機関は早期発見とタイムリーな介入を重視しており、より効率的で利用しやすい治療法への需要がさらに高まっています。

技術の進歩はどのように真菌性角膜炎治療を形成しているか？

眼科治療薬の開発と診断における技術革新は、真菌性角膜炎治療の成果を高める上で重要な役割を果たしています。ポリメラーゼ連鎖反応（PCR）アッセイ、共焦点顕微鏡、次世代シークエンシングなどの高度な診断技術は、真菌同定の精度と速度を向上させ、タイムリーで的を絞った治療を可能にしています。眼科における人工知能（AI）の統合も早期発見能力を変革しており、AIを搭載した画像診断ツールは真菌性角膜炎と細菌やウイルス性角膜感染症との鑑別に役立っています。誤診の結果、治療が遅れたり、効果がなかったりすることが多く、患者の転帰を悪化させるため、これは特に重要です。

革新的なドラッグデリバリーシステムもまた、真菌性角膜炎治療に革命をもたらしています。研究開発者は、薬剤の有効性を高め、治療期間を短縮するために、徐放性点眼剤、ナノ粒子ベースの点眼剤、マイクロニードル薬剤デリバリーパッチを開発しています。局所抗真菌遺伝子治療の出現も有望な開発であり、耐性真菌株に対する長期的な解決策の可能性を提供しています。さらに、3Dバイオプリンティング技術は角膜組織再生のために研究されており、移植を必要とする重度の角膜障害を持つ患者に代替手段を提供しています。真菌性角膜炎の有病率の増加に伴い、これらの技術的ブレークスルーは治療へのアクセス性と有効性を大幅に改善し、眼科治療薬の新時代への道を開くと期待されています。

真菌性角膜炎治療の需要を牽引している主要市場セグメントは？

真菌性角膜炎治療の需要を牽引しているのは、眼科クリニック、専門病院、研究所、製薬会社など、複数のヘルスケア部門です。眼科病院およびクリニックは、真菌性角膜炎患者の主要な治療ポイントとして機能しているため、最大の市場シェアを占めています。これらの施設では高度な診断ツールが利用できるようになったため、早期発見率が向上し、患者の予後改善につながりました。専門製薬企業もまた、薬剤耐性の問題に対処する新規抗真菌製剤や併用療法の開発に注力し、極めて重要な役割を果たしています。さらに、オンライン薬局の台頭により、特にヘルスケアのインフラが限られている発展途上地域では、抗真菌薬へのアクセスがより容易になっています。

また、学術研究機関やバイオベンチャー企業も、抗真菌ペプチド、バイオエンジニアリング眼球組織、個別化医療アプローチなどの新たな治療イノベーションに投資することで、市場の成長に貢献しています。真菌性角膜炎に対する認識の高まりは、ヘルスケア組織による患者教育イニシアチブの増加と相まって、治療プロトコルの遵守を高める原動力となっています。さらに、視覚関連疾患との闘いを目的とした政府支援のヘルスケアプログラムの拡大が、市場の需要をさらに促進しています。世界の眼科医療支出の増加が続く中、真菌性角膜炎治療市場は着実な成長が見込まれており、継続的な進歩が眼科抗真菌療法の将来を形成しています。

市場成長を牽引する主な要因とは？

真菌性角膜炎治療市場の成長は、真菌感染症の有病率の増加、抗真菌薬開発の進歩、診断技術の向上など、いくつかの要因によって牽引されています。特に、糖尿病、HIV/AIDS、コルチコステロイドの長期使用などによる免疫不全患者の増加は、より効果的な真菌性角膜炎治療薬に対する需要の拡大に大きく寄与しています。さらに、しばしば不衛生な習慣と関連するコンタクトレンズの採用拡大が、角膜炎患者の急増につながり、市場の成長をさらに促進しています。

AIを活用した診断ツール、ナノ粒子製剤、徐放性抗真菌療法などの技術革新は、治療効果と患者のコンプライアンスを向上させています。また、遠隔医療やデジタルヘルスケアプラットフォームの統合により、特に農村部や十分なサービスを受けていない地域における真菌性角膜炎治療へのアクセスが向上しています。さらに、製薬会社はバイオアベイラビリティが改善され、副作用の少ない次世代抗真菌薬を開発するため、研究開発イニシアチブに多額の投資を行っています。個別化医療、角膜再生治療、低侵襲治療への重点の高まりは、真菌性角膜炎治療の展望を再形成すると予想されます。新規治療薬に対する規制当局の承認が増加し、真菌性眼感染症に対する認識が高まり続けていることから、市場は今後数年間で大幅に拡大する見通しです。

セグメント

クラス（アゾール系、エキノカンディン系、ポリエン系、アリルアミン系、その他薬剤クラス別）;適応症（皮膚糸状菌症、アスペルギルス症、カンジダ症、その他適応症）;剤形（経口薬剤形、軟膏剤形、粉末剤形、その他剤形）;流通チャネル（病院薬局流通チャネル、小売薬局流通チャネル、その他流通チャネル）

調査対象企業の例

• AbbVie Inc.
• Allergan（a subsidiary of AbbVie）
• Alvogen
• Amgen Inc.
• Aurolab
• Bausch Health Companies Inc.
• Bayer AG
• Bristol-Myers Squibb Company
• Eyevance Pharmaceuticals LLC
• Gilead Sciences, Inc.
• Glenmark Pharmaceuticals Ltd.
• Johnson & Johnson Vision Care, Inc.
• Leadiant Biosciences, Inc.
• Merck & Co., Inc.
• Novartis AG
• Novo Holdings A/S（Xellia Pharmaceuticals）
• Pfizer Inc.
• Sanofi
• Santen Pharmaceutical Co., Ltd.
• Takeda Pharmaceutical Company Limited

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMにクエリーする代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Fungal Keratitis Treatment Market to Reach US$1.4 Billion by 2030

The global market for Fungal Keratitis Treatment estimated at US$965.2 Million in the year 2024, is expected to reach US$1.4 Billion by 2030, growing at a CAGR of 6.1% over the analysis period 2024-2030. Azoles, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$627.5 Million by the end of the analysis period. Growth in the Echinocandins segment is estimated at 7.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$263.0 Million While China is Forecast to Grow at 9.5% CAGR

The Fungal Keratitis Treatment market in the U.S. is estimated at US$263.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$279.1 Million by the year 2030 trailing a CAGR of 9.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 5.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global Fungal Keratitis Treatment Market - Key Trends & Drivers Summarized

Why is the Demand for Effective Fungal Keratitis Treatment Rising?

Fungal keratitis, a severe corneal infection caused by fungal pathogens such as Fusarium, Aspergillus, and Candida, has emerged as a growing global health concern, particularly in tropical and subtropical regions. The rising incidence of this condition is primarily linked to increasing agricultural activities, trauma-related infections, contact lens misuse, and compromised immune systems. Delayed diagnosis and inadequate treatment can lead to corneal scarring, vision impairment, or even blindness, necessitating more effective therapeutic interventions. Traditional antifungal treatments, including natamycin, amphotericin B, and voriconazole, remain the standard options; however, drug resistance and limited bioavailability continue to pose challenges. The demand for more advanced, targeted, and less invasive fungal keratitis treatments has grown substantially, leading to increased research into novel antifungal agents, combination therapies, and innovative drug delivery mechanisms.

Pharmaceutical companies and research institutions are actively developing next-generation antifungal drugs that offer improved corneal penetration and better efficacy against resistant fungal strains. Nanotechnology-based formulations, such as nanoemulsions and liposomal drug carriers, are being explored to enhance drug absorption and prolong the retention time of antifungal agents on the ocular surface. Additionally, ongoing clinical trials investigating new treatment modalities, such as antifungal peptides and immunotherapy approaches, indicate a shift toward personalized medicine in fungal keratitis treatment. Given the significant morbidity associated with the disease, global health organizations are emphasizing early detection and timely intervention, further driving demand for more efficient and accessible treatment options.

How are Technological Advancements Shaping Fungal Keratitis Treatment?

Technological innovations in ophthalmic drug development and diagnostics have played a crucial role in enhancing fungal keratitis treatment outcomes. Advanced diagnostic techniques, including polymerase chain reaction (PCR) assays, confocal microscopy, and next-generation sequencing, are improving the accuracy and speed of fungal identification, allowing for timely and targeted treatment. The integration of artificial intelligence (AI) in ophthalmology is also transforming early detection capabilities, with AI-powered imaging tools aiding in the differentiation of fungal keratitis from bacterial and viral corneal infections. This is particularly significant, as misdiagnosis often results in delayed or ineffective treatment, exacerbating patient outcomes.

Innovative drug delivery systems are also revolutionizing fungal keratitis treatment. Researchers are developing sustained-release ocular inserts, nanoparticle-based eye drops, and microneedle drug delivery patches to enhance drug efficacy and reduce treatment duration. The emergence of topical antifungal gene therapy is another promising development, offering potential long-term solutions for resistant fungal strains. Additionally, 3D bioprinting technology is being explored for corneal tissue regeneration, providing an alternative for patients with severe corneal damage requiring transplantation. With the increasing prevalence of fungal keratitis, these technological breakthroughs are expected to significantly improve treatment accessibility and effectiveness, paving the way for a new era of ophthalmic therapeutics.

Which Key Market Segments Are Driving Demand for Fungal Keratitis Treatment?

The demand for fungal keratitis treatment is being driven by multiple healthcare sectors, including ophthalmology clinics, specialty hospitals, research laboratories, and pharmaceutical companies. Ophthalmic hospitals and clinics account for the largest market share, as they serve as the primary point of care for fungal keratitis patients. The increasing availability of advanced diagnostic tools in these facilities has improved early detection rates, leading to better patient outcomes. Specialty pharmaceutical firms are also playing a pivotal role, focusing on the development of novel antifungal formulations and combination therapies that address drug resistance issues. Additionally, the rise of online pharmacies has facilitated greater access to antifungal medications, particularly in developing regions where healthcare infrastructure remains limited.

Academic research institutions and biotech startups are also contributing to market growth by investing in new therapeutic innovations, such as antifungal peptides, bioengineered ocular tissues, and personalized medicine approaches. The growing awareness of fungal keratitis, coupled with increasing patient education initiatives by healthcare organizations, has driven greater adherence to treatment protocols. Moreover, the expansion of government-backed healthcare programs aimed at combating vision-related diseases is further fueling market demand. As global ophthalmic healthcare spending continues to rise, the fungal keratitis treatment market is expected to experience steady growth, with ongoing advancements shaping the future of ocular antifungal therapies.

What Key Factors Are Driving Market Growth?

The growth in the fungal keratitis treatment market is driven by several factors, including the increasing prevalence of fungal infections, advancements in antifungal drug development, and improvements in diagnostic technologies. The rise in immunocompromised patient populations, particularly due to conditions such as diabetes, HIV/AIDS, and prolonged corticosteroid use, has significantly contributed to the growing demand for more effective fungal keratitis treatments. Additionally, the expanding adoption of contact lenses, often associated with poor hygiene practices, has led to a surge in keratitis cases, further propelling market growth.

Technological innovations, including AI-powered diagnostic tools, nanoparticle drug formulations, and sustained-release antifungal therapies, are enhancing treatment efficacy and patient compliance. The integration of telemedicine and digital healthcare platforms is also improving access to fungal keratitis treatment, particularly in rural and underserved regions. Moreover, pharmaceutical companies are investing heavily in R&D initiatives to develop next-generation antifungal agents with improved bioavailability and fewer side effects. The growing emphasis on personalized medicine, regenerative corneal therapies, and minimally invasive treatment approaches is expected to reshape the fungal keratitis treatment landscape. As regulatory approvals for novel therapies increase and awareness about fungal eye infections continues to rise, the market is poised for substantial expansion in the coming years.

SCOPE OF STUDY:

The report analyzes the Fungal Keratitis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Class (Azoles, Echinocandins, Polyenes, Allylamines, Other Drug Classes); Indication (Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Other Indications); Dosage Form (Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form, Other Dosage Forms); Distribution Channel (Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

• AbbVie Inc.
• Allergan (a subsidiary of AbbVie)
• Alvogen
• Amgen Inc.
• Aurolab
• Bausch Health Companies Inc.
• Bayer AG
• Bristol-Myers Squibb Company
• Eyevance Pharmaceuticals LLC
• Gilead Sciences, Inc.
• Glenmark Pharmaceuticals Ltd.
• Johnson & Johnson Vision Care, Inc.
• Leadiant Biosciences, Inc.
• Merck & Co., Inc.
• Novartis AG
• Novo Holdings A/S (Xellia Pharmaceuticals)
• Pfizer Inc.
• Sanofi
• Santen Pharmaceutical Co., Ltd.
• Takeda Pharmaceutical Company Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Fungal Keratitis Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Ocular Fungal Infections in Tropical and Subtropical Regions Drives Demand for Effective Treatments
  • Increased Incidence of Contact Lens-Associated Infections Throws the Spotlight on Antifungal Ophthalmics
  • Growing Awareness and Early Diagnosis Through Eye Health Campaigns Strengthens Market for Topical Antifungals
  • Expansion of Clinical Research in Polyenes, Azoles, and Echinocandins Boosts Pipeline for Ocular Antifungal Drugs
  • Development of Nanocarrier and Sustained-Release Eye Drop Formulations Enhances Drug Retention and Efficacy
  • Rise in Corneal Injuries and Trauma Cases, Especially in Agriculture-Intensive Economies, Supports Market Demand
  • Emergence of Resistance to Conventional Antifungals Fuels Demand for Novel Mechanism-Based Therapies
  • Increased Availability of FDA and EMA-Approved Treatments Improves Access in Developed Markets
  • Use of Combination Therapies With Steroids and Antifungals Enhances Treatment Outcomes in Severe Cases
  • Surge in Hospital-Based and Outpatient Ophthalmology Services Expands Access to Prescription Antifungals
  • Adoption of In Vivo Imaging and Confocal Microscopy Supports Faster Diagnosis and Patient Stratification
  • Growth of Personalized Medicine and Targeted Ocular Drug Delivery Systems Enhances Clinical Adoption
  • Availability of Fungal Diagnostic Kits and Staining Techniques Promotes Awareness Among Eye Care Professionals
  • Increased Public Funding and Grants for Vision Preservation Programs Support Research Into Rare Fungal Pathogens
  • Expansion of Generic Antifungal Manufacturers in Emerging Markets Improves Affordability and Access
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Fungal Keratitis Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Fungal Keratitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Fungal Keratitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Azoles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Azoles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Azoles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Echinocandins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Echinocandins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Echinocandins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Polyenes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Polyenes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Polyenes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Allylamines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Allylamines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Allylamines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Oral Drugs Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Oral Drugs Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Oral Drugs Dosage Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Ointments Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Ointments Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Ointments Dosage Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Powders Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Powders Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Powders Dosage Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Other Dosage Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Other Dosage Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Other Dosage Forms by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Hospital Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Retails Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Retails Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Retails Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Dermatophytosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Dermatophytosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Dermatophytosis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Aspergillosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Aspergillosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Aspergillosis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Candidiasis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Candidiasis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Candidiasis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Fungal Keratitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 53: USA Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for Fungal Keratitis Treatment by Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Fungal Keratitis Treatment by Dosage Form - Percentage Breakdown of Value Sales for Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: USA 15-Year Perspective for Fungal Keratitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 62: USA Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: USA 15-Year Perspective for Fungal Keratitis Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for Fungal Keratitis Treatment by Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Canada 15-Year Perspective for Fungal Keratitis Treatment by Dosage Form - Percentage Breakdown of Value Sales for Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Canada 15-Year Perspective for Fungal Keratitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 74: Canada Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Canada Historic Review for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Canada 15-Year Perspective for Fungal Keratitis Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications for the Years 2015, 2025 & 2030
• JAPAN
  • Fungal Keratitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Japan 15-Year Perspective for Fungal Keratitis Treatment by Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: Japan 15-Year Perspective for Fungal Keratitis Treatment by Dosage Form - Percentage Breakdown of Value Sales for Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
  • TABLE 83: Japan Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Japan Historic Review for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: Japan 15-Year Perspective for Fungal Keratitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 86: Japan Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Japan Historic Review for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: Japan 15-Year Perspective for Fungal Keratitis Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications for the Years 2015, 2025 & 2030
• CHINA
  • Fungal Keratitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 89: China Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: China Historic Review for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: China 15-Year Perspective for Fungal Keratitis Treatment by Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 92: China Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: China Historic Review for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: China 15-Year Perspective for Fungal Keratitis Treatment by Dosage Form - Percentage Breakdown of Value Sales for Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
  • TABLE 95: China Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: China Historic Review for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: China 15-Year Perspective for Fungal Keratitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 98: China Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: China Historic Review for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: China 15-Year Perspective for Fungal Keratitis Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications for the Years 2015, 2025 & 2030
• EUROPE
  • Fungal Keratitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Fungal Keratitis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Europe 15-Year Perspective for Fungal Keratitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Europe 15-Year Perspective for Fungal Keratitis Treatment by Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 107: Europe Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: Europe 15-Year Perspective for Fungal Keratitis Treatment by Dosage Form - Percentage Breakdown of Value Sales for Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
  • TABLE 110: Europe Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: Europe 15-Year Perspective for Fungal Keratitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 113: Europe Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Europe Historic Review for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: Europe 15-Year Perspective for Fungal Keratitis Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications for the Years 2015, 2025 & 2030
• FRANCE
  • Fungal Keratitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 116: France Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: France Historic Review for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: France 15-Year Perspective for Fungal Keratitis Treatment by Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 119: France Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: France Historic Review for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: France 15-Year Perspective for Fungal Keratitis Treatment by Dosage Form - Percentage Breakdown of Value Sales for Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
  • TABLE 122: France Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: France Historic Review for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: France 15-Year Perspective for Fungal Keratitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 125: France Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: France Historic Review for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: France 15-Year Perspective for Fungal Keratitis Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications for the Years 2015, 2025 & 2030
• GERMANY
  • Fungal Keratitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 128: Germany Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Germany Historic Review for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Germany 15-Year Perspective for Fungal Keratitis Treatment by Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 131: Germany Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Germany Historic Review for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Germany 15-Year Perspective for Fungal Keratitis Treatment by Dosage Form - Percentage Breakdown of Value Sales for Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
  • TABLE 134: Germany Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Germany Historic Review for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Germany 15-Year Perspective for Fungal Keratitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 137: Germany Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Germany Historic Review for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Germany 15-Year Perspective for Fungal Keratitis Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 140: Italy Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Italy Historic Review for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Italy 15-Year Perspective for Fungal Keratitis Treatment by Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 143: Italy Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Italy Historic Review for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Italy 15-Year Perspective for Fungal Keratitis Treatment by Dosage Form - Percentage Breakdown of Value Sales for Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
  • TABLE 146: Italy Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Italy Historic Review for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Italy 15-Year Perspective for Fungal Keratitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 149: Italy Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Italy Historic Review for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Italy 15-Year Perspective for Fungal Keratitis Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Fungal Keratitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 152: UK Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: UK Historic Review for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: UK 15-Year Perspective for Fungal Keratitis Treatment by Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 155: UK Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: UK Historic Review for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: UK 15-Year Perspective for Fungal Keratitis Treatment by Dosage Form - Percentage Breakdown of Value Sales for Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
  • TABLE 158: UK Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: UK Historic Review for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: UK 15-Year Perspective for Fungal Keratitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 161: UK Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: UK Historic Review for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: UK 15-Year Perspective for Fungal Keratitis Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 164: Spain Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Spain Historic Review for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Spain 15-Year Perspective for Fungal Keratitis Treatment by Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 167: Spain Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Spain Historic Review for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Spain 15-Year Perspective for Fungal Keratitis Treatment by Dosage Form - Percentage Breakdown of Value Sales for Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
  • TABLE 170: Spain Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Spain Historic Review for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: Spain 15-Year Perspective for Fungal Keratitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 173: Spain Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Spain Historic Review for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: Spain 15-Year Perspective for Fungal Keratitis Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 176: Russia Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Russia Historic Review for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Russia 15-Year Perspective for Fungal Keratitis Treatment by Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 179: Russia Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Russia Historic Review for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Russia 15-Year Perspective for Fungal Keratitis Treatment by Dosage Form - Percentage Breakdown of Value Sales for Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
  • TABLE 182: Russia Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Russia Historic Review for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Russia 15-Year Perspective for Fungal Keratitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 185: Russia Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Russia Historic Review for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Russia 15-Year Perspective for Fungal Keratitis Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Europe Historic Review for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Europe 15-Year Perspective for Fungal Keratitis Treatment by Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Europe Historic Review for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Europe 15-Year Perspective for Fungal Keratitis Treatment by Dosage Form - Percentage Breakdown of Value Sales for Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Europe Historic Review for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Europe 15-Year Perspective for Fungal Keratitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Europe Historic Review for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Europe 15-Year Perspective for Fungal Keratitis Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Fungal Keratitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Fungal Keratitis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 15-Year Perspective for Fungal Keratitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 15-Year Perspective for Fungal Keratitis Treatment by Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 15-Year Perspective for Fungal Keratitis Treatment by Dosage Form - Percentage Breakdown of Value Sales for Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
  • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Asia-Pacific Historic Review for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Asia-Pacific 15-Year Perspective for Fungal Keratitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Asia-Pacific Historic Review for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Asia-Pacific 15-Year Perspective for Fungal Keratitis Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Fungal Keratitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 215: Australia Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Australia Historic Review for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Australia 15-Year Perspective for Fungal Keratitis Treatment by Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 218: Australia Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Australia Historic Review for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Australia 15-Year Perspective for Fungal Keratitis Treatment by Dosage Form - Percentage Breakdown of Value Sales for Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
  • TABLE 221: Australia Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Australia Historic Review for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Australia 15-Year Perspective for Fungal Keratitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 224: Australia Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Australia Historic Review for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Australia 15-Year Perspective for Fungal Keratitis Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications for the Years 2015, 2025 & 2030
• INDIA
  • Fungal Keratitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 227: India Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: India Historic Review for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: India 15-Year Perspective for Fungal Keratitis Treatment by Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 230: India Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: India Historic Review for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: India 15-Year Perspective for Fungal Keratitis Treatment by Dosage Form - Percentage Breakdown of Value Sales for Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
  • TABLE 233: India Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: India Historic Review for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: India 15-Year Perspective for Fungal Keratitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 236: India Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: India Historic Review for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: India 15-Year Perspective for Fungal Keratitis Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 239: South Korea Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: South Korea Historic Review for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: South Korea 15-Year Perspective for Fungal Keratitis Treatment by Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 242: South Korea Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: South Korea Historic Review for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: South Korea 15-Year Perspective for Fungal Keratitis Treatment by Dosage Form - Percentage Breakdown of Value Sales for Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
  • TABLE 245: South Korea Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: South Korea Historic Review for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: South Korea 15-Year Perspective for Fungal Keratitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 248: South Korea Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: South Korea Historic Review for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: South Korea 15-Year Perspective for Fungal Keratitis Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Asia-Pacific Historic Review for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Asia-Pacific 15-Year Perspective for Fungal Keratitis Treatment by Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Asia-Pacific Historic Review for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Asia-Pacific 15-Year Perspective for Fungal Keratitis Treatment by Dosage Form - Percentage Breakdown of Value Sales for Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
  • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Asia-Pacific Historic Review for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Rest of Asia-Pacific 15-Year Perspective for Fungal Keratitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Rest of Asia-Pacific Historic Review for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Rest of Asia-Pacific 15-Year Perspective for Fungal Keratitis Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Fungal Keratitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Fungal Keratitis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Latin America 15-Year Perspective for Fungal Keratitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Latin America 15-Year Perspective for Fungal Keratitis Treatment by Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Latin America 15-Year Perspective for Fungal Keratitis Treatment by Dosage Form - Percentage Breakdown of Value Sales for Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
  • TABLE 272: Latin America Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Latin America Historic Review for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Latin America 15-Year Perspective for Fungal Keratitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 275: Latin America Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Latin America Historic Review for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Latin America 15-Year Perspective for Fungal Keratitis Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 278: Argentina Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Argentina Historic Review for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Argentina 15-Year Perspective for Fungal Keratitis Treatment by Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 281: Argentina Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Argentina Historic Review for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Argentina 15-Year Perspective for Fungal Keratitis Treatment by Dosage Form - Percentage Breakdown of Value Sales for Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
  • TABLE 284: Argentina Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Argentina Historic Review for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: Argentina 15-Year Perspective for Fungal Keratitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 287: Argentina Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Argentina Historic Review for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Argentina 15-Year Perspective for Fungal Keratitis Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 290: Brazil Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Brazil Historic Review for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Brazil 15-Year Perspective for Fungal Keratitis Treatment by Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 293: Brazil Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Brazil Historic Review for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Brazil 15-Year Perspective for Fungal Keratitis Treatment by Dosage Form - Percentage Breakdown of Value Sales for Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
  • TABLE 296: Brazil Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Brazil Historic Review for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Brazil 15-Year Perspective for Fungal Keratitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 299: Brazil Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Brazil Historic Review for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Brazil 15-Year Perspective for Fungal Keratitis Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 302: Mexico Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Mexico Historic Review for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Mexico 15-Year Perspective for Fungal Keratitis Treatment by Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 305: Mexico Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Mexico Historic Review for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: Mexico 15-Year Perspective for Fungal Keratitis Treatment by Dosage Form - Percentage Breakdown of Value Sales for Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
  • TABLE 308: Mexico Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Mexico Historic Review for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Mexico 15-Year Perspective for Fungal Keratitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 311: Mexico Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Mexico Historic Review for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 313: Mexico 15-Year Perspective for Fungal Keratitis Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Latin America Historic Review for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 316: Rest of Latin America 15-Year Perspective for Fungal Keratitis Treatment by Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Latin America Historic Review for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 319: Rest of Latin America 15-Year Perspective for Fungal Keratitis Treatment by Dosage Form - Percentage Breakdown of Value Sales for Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
  • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Latin America Historic Review for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 322: Rest of Latin America 15-Year Perspective for Fungal Keratitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Rest of Latin America Historic Review for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 325: Rest of Latin America 15-Year Perspective for Fungal Keratitis Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Fungal Keratitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Fungal Keratitis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 328: Middle East 15-Year Perspective for Fungal Keratitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 331: Middle East 15-Year Perspective for Fungal Keratitis Treatment by Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 334: Middle East 15-Year Perspective for Fungal Keratitis Treatment by Dosage Form - Percentage Breakdown of Value Sales for Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
  • TABLE 335: Middle East Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Middle East Historic Review for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 337: Middle East 15-Year Perspective for Fungal Keratitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 338: Middle East Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Middle East Historic Review for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 340: Middle East 15-Year Perspective for Fungal Keratitis Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 341: Iran Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Iran Historic Review for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 343: Iran 15-Year Perspective for Fungal Keratitis Treatment by Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 344: Iran Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Iran Historic Review for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 346: Iran 15-Year Perspective for Fungal Keratitis Treatment by Dosage Form - Percentage Breakdown of Value Sales for Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
  • TABLE 347: Iran Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Iran Historic Review for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 349: Iran 15-Year Perspective for Fungal Keratitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 350: Iran Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Iran Historic Review for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 352: Iran 15-Year Perspective for Fungal Keratitis Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 353: Israel Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Israel Historic Review for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 355: Israel 15-Year Perspective for Fungal Keratitis Treatment by Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 356: Israel Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Israel Historic Review for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 358: Israel 15-Year Perspective for Fungal Keratitis Treatment by Dosage Form - Percentage Breakdown of Value Sales for Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
  • TABLE 359: Israel Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Israel Historic Review for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 361: Israel 15-Year Perspective for Fungal Keratitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 362: Israel Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Israel Historic Review for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 364: Israel 15-Year Perspective for Fungal Keratitis Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Saudi Arabia Historic Review for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 367: Saudi Arabia 15-Year Perspective for Fungal Keratitis Treatment by Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Saudi Arabia Historic Review for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 370: Saudi Arabia 15-Year Perspective for Fungal Keratitis Treatment by Dosage Form - Percentage Breakdown of Value Sales for Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
  • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Saudi Arabia Historic Review for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 373: Saudi Arabia 15-Year Perspective for Fungal Keratitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Saudi Arabia Historic Review for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 376: Saudi Arabia 15-Year Perspective for Fungal Keratitis Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 377: UAE Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 378: UAE Historic Review for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 379: UAE 15-Year Perspective for Fungal Keratitis Treatment by Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 380: UAE Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 381: UAE Historic Review for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 382: UAE 15-Year Perspective for Fungal Keratitis Treatment by Dosage Form - Percentage Breakdown of Value Sales for Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
  • TABLE 383: UAE Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 384: UAE Historic Review for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 385: UAE 15-Year Perspective for Fungal Keratitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 386: UAE Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 387: UAE Historic Review for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 388: UAE 15-Year Perspective for Fungal Keratitis Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Rest of Middle East Historic Review for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 391: Rest of Middle East 15-Year Perspective for Fungal Keratitis Treatment by Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Middle East Historic Review for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 394: Rest of Middle East 15-Year Perspective for Fungal Keratitis Treatment by Dosage Form - Percentage Breakdown of Value Sales for Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
  • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Middle East Historic Review for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 397: Rest of Middle East 15-Year Perspective for Fungal Keratitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Rest of Middle East Historic Review for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 400: Rest of Middle East 15-Year Perspective for Fungal Keratitis Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications for the Years 2015, 2025 & 2030
• AFRICA
  • Fungal Keratitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 401: Africa Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Africa Historic Review for Fungal Keratitis Treatment by Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 403: Africa 15-Year Perspective for Fungal Keratitis Treatment by Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 404: Africa Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Africa Historic Review for Fungal Keratitis Treatment by Dosage Form - Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 406: Africa 15-Year Perspective for Fungal Keratitis Treatment by Dosage Form - Percentage Breakdown of Value Sales for Oral Drugs Dosage Form, Ointments Dosage Form, Powders Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
  • TABLE 407: Africa Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Africa Historic Review for Fungal Keratitis Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 409: Africa 15-Year Perspective for Fungal Keratitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retails Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 410: Africa Recent Past, Current & Future Analysis for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Africa Historic Review for Fungal Keratitis Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 412: Africa 15-Year Perspective for Fungal Keratitis Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication and Other Indications for the Years 2015, 2025 & 2030

IV. COMPETITION